Long-lived fusions of human haematological tumour cells and B-lymphoblastoid cells induce tumour antigen-specific cytotoxic T-cell responses in vitro
- PMID: 22305004
- DOI: 10.1016/j.imbio.2011.12.001
Long-lived fusions of human haematological tumour cells and B-lymphoblastoid cells induce tumour antigen-specific cytotoxic T-cell responses in vitro
Abstract
Tumour-specific cytotoxic T-cells (CTL) are important anti-cancer immune effectors. Most tumour cells, however, do not stimulate effective anti-tumour immune responses, in vivo or in vitro. To enhance tumour cell immunogenicity, we fused human tumour cells from haematological malignancies with the B-lymphoblastoid cell line (LCL), HMy2, to generate a panel of long-lived, self replicating LCL/tumour hybrid cell lines. The LCL/tumour hybrid cell lines expressed HLA class I and class II molecules, CD80 and CD86, and a range of known tumour associated antigens (TAAs). In vitro stimulation of PBLs from healthy, HLA-A2+ individuals by hybrid cell lines induced tumour antigen-specific CTLs to TAAs, including survivin, MAGE-A1, NY-ESO-1 and WT-1. Individual hybrid cell lines simultaneously induced CTL to multiple TAAs. In vitro stimulation of PBL from 2 patients with acute myeloid leukaemia by autologous LCL/tumour hybrid cell lines induced CTL capable of killing the patient's own tumour cells. Our data show, for the first time, that hybrid cell lines formed by fusion of HMy2 cells and haematological tumour cells induce tumour- and tumour antigen-specific cytotoxic T-cell responses in vitro. Hybrid cell lines such as those described may represent novel reagents for use in the immunotherapy of haematological malignancies.
Copyright © 2011 Elsevier GmbH. All rights reserved.
Similar articles
-
In vitro evaluation of human hybrid cell lines generated by fusion of B-lymphoblastoid cells and ex vivo tumour cells as candidate vaccines for haematological malignancies.Vaccine. 2012 Oct 12;30(46):6578-87. doi: 10.1016/j.vaccine.2012.08.032. Epub 2012 Aug 30. Vaccine. 2012. PMID: 22939910
-
Hybrid cells formed by fusion of Epstein-Barr virus-associated B-lymphoblastoid cells and either marrow-derived or solid tumour-derived cell lines display different co-stimulatory phenotypes and abilities to activate allogeneic T-cell responses in vitro.Tissue Antigens. 2006 Aug;68(2):115-26. doi: 10.1111/j.1399-0039.2006.00623.x. Tissue Antigens. 2006. PMID: 16866881
-
Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients.Cancer Res. 1997 Feb 15;57(4):735-41. Cancer Res. 1997. PMID: 9044853
-
Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer.J Clin Pathol. 2001 Sep;54(9):669-74. doi: 10.1136/jcp.54.9.669. J Clin Pathol. 2001. PMID: 11533070 Free PMC article. Review.
-
Immunotherapy II: Antigens, receptors and costimulation.Cancer Metastasis Rev. 1996 Sep;15(3):329-49. doi: 10.1007/BF00046346. Cancer Metastasis Rev. 1996. PMID: 9034595 Review.
Cited by
-
Antigen presenting cell/ tumor cell fusion vaccines for cancer immunotherapy.Hum Vaccin Immunother. 2013 Jul;9(7):1545-8. doi: 10.4161/hv.24235. Epub 2013 Mar 8. Hum Vaccin Immunother. 2013. PMID: 23475129 Free PMC article. Review.
-
In vitro Generation of Cytotoxic T Cells With Potential for Adoptive Tumor Immunotherapy of Multiple Myeloma.Front Immunol. 2019 Aug 2;10:1792. doi: 10.3389/fimmu.2019.01792. eCollection 2019. Front Immunol. 2019. PMID: 31428094 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
